

Please add the following new claims.

-- 9. (new) The hematopoietic cell expansion media of claim 1 comprising a recombinant human flt3-ligand.--

-- 10. (new) The method of claim 2 wherein the flt3-L is a recombinant human flt3-ligand.--

-- 11. (new) The hematopoietic cell expansion media of claim 3 comprising a recombinant human flt3-ligand.--

-- 12. (new) The hematopoietic cell expansion media of claim 4 comprising a recombinant human flt3-ligand.--

-- 13. (new) The hematopoietic cell expansion media of claim 5 comprising a recombinant human flt3-ligand.--

-- 14. (new) The hematopoietic cell expansion media of claim 6 comprising a recombinant human flt3-ligand.--

-- 15. (new) The hematopoietic cell expansion media of claim 7 comprising a recombinant human flt3-ligand.--

-- 16. (new) The hematopoietic cell expansion media of claim 8 comprising a recombinant human flt3-ligand.--

-- 17. (new) The hematopoietic cell expansion media of claim 1 further comprising a cellular growth factor in an amount sufficient to cause hematopoietic cell expansion.--

-- 18. (new) The method of claim 2 wherein the cells are further contacted with a cellular growth factor in an amount sufficient to cause hematopoietic cell expansion.--

-- 19. (new) The hematopoietic cell expansion media of claim 1 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids

28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.--

-- 20. (new) The method of claim 2 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.--

-- 21. (new) The hematopoietic cell expansion media of claim 3 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.--

-- 22. (new) The hematopoietic cell expansion media of claim 4 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.--

-- 23. (new) The hematopoietic cell expansion media of claim 5 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.--

-- 24. (new) The hematopoietic cell expansion media of claim 6 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.--

-- 25. (new) The hematopoietic cell expansion media of claim 7 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.--

-- 26. (new) The hematopoietic cell expansion media of claim 8 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.—

*E*  
-- 27. (new) The hematopoietic cell expansion media of claim 17 wherein the flt3-ligand is a recombinant human flt3-ligand.—

*Q*  
-- 28. (new) The method of claim 18 wherein the flt3-ligand is a recombinant human flt3-ligand.—

-- 29. (new) The hematopoietic cell expansion media of claim 17 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.—

-- 30. (new) The method of claim 18 wherein the flt3-ligand is selected from the group consisting of a soluble polypeptide comprising amino acids 28-160 of SEQ ID NO:6 and a soluble polypeptide that comprises an amino acid sequence that is at least 80% identical to the amino acids 28-160 of SEQ ID NO:6.—

### Remarks

Applicants note the Examiner's remarks regarding numbering of the claims, and apologize for any confusion that may have resulted. Applicants will maintain the claim numbering as established by the Examiner.

Claims 1 and 2 have been amended to clarify that which is claimed, and new claims 9-30 are presented. New dependent claims 9-16 are fully supported by the specification at, for example, page 7, lines 7-8 and page 13, lines 16-17. New claims 17 and 18 are supported by claims 1 and 2 as filed. Support for new claims 19-30 can be found in the in the specification at, *inter alia*, page 7, lines 28-31 and page 8, lines 8-10. Entry of these amendments is requested.